#SFHS2610287VNotice Regarding Prices of Pharmaceutical Specialties
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This law sets the prices for specific pharmaceutical products in France starting May 1, 2026. It affects companies involved in the production and distribution of ustekinumab injectable solutions, ensuring uniform pricing across brands such as IMULDOSA, OTULFI, PYZCHIVA, STEQEYMA, USRENTY, UZPRUVO, WEZENLA, and YESINTEK.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Sets uniform prices for ustekinumab injectable solutions
- Effective from May 1, 2026
- Applies to multiple pharmaceutical brands
Obligations
What this law requires
Pharmaceutical companies must set the price for ustekinumab injectable solutions according to the fixed prices listed in the law starting from May 1, 2026.
Each brand of ustekinumab injectable solutions must adhere to the established price of €1,020.04 ex VAT and €1,145.89 including VAT.
Pharmaceutical companies must ensure uniform pricing across their brands including IMULDOSA, OTULFI, PYZCHIVA, STEQEYMA, USRENTY, UZPRUVO, WEZENLA, and YESINTEK.